Contract Development and Manufacturing Organizations (CDMOs) have a great role in the development of safe drugs, vaccines, and other pharmaceuticals. They can address the problems of multiple vendors and manufacturers, run more than one line of development at one time, and simplify contract negotiations.
It’s estimated that two-thirds of pharma development is outsourced1, and this increased demand has those companies confronting things that were once the sole concerns of the pharma companies. CDMOs often are in charge of production, formulation, and various analytical services.
Outsourcing the development of drugs is overwhelmingly cost-effective; because it shortens the time for the drug to come to market, it can save almost 45 million in costs2. A study by Tufts Center for the Study of Drug Development compared CDMO work to a multi-source model and an average of 14.2 weeks was saved with the single source.
To address the demand, the Pharma & Biopharma Outsourcing Association (PBOA) sponsored a dedicated space for CMOs and CDMOs this year on the show floor at INTERPHEX 2018 in April. There also were targeted conference sessions on contract manufacturing at the show.
The new area was designed to meet industry growth that has increased the need for CMOs and CDMOs and the increased demand for drug formulation and production outside of conventional contract services. It also addressed the current need to reduce costs.
The CMO Pavilion was intended to provide a focus point for contract manufacturers and other service providers to the bio/pharma space during INTERPHEX.
PBOA is one of the largest trade organizations devoted to advancing the regulatory, legislative, and general business interests of CMOs and CDMOs. Their aim is to provide services to help pharma organizations develop drugs, vaccines, and other biologic treatments.
In addition to the dedicated conference program, the organization hosted a networking event as well as private networking rooms.
“Our support and involvement in INTERPHEX underscores our commitment to expand and advance our members’ and the global community’s knowledge-base at this leading industry forum,” Gil Roth, president of the PBOA, told Pharmaceutical Processing prior to the show.
PBOA member companies that participated included Adents, Alcami, Althea, Avista Pharma Solutions, Berkshire Sterile Manufacturing, CMIC CMO USA, Grand River Aseptic Manufacturing Inc., LSNE Contract Manufacturing, Optel Group, PCI Pharma Services, Pfizer CentreOne, Piramal Pharma Solutions, Safebridge Consultants, Therapure Biomanufacturing, and Thermo Fisher Scientific.
PBOA previously was featured at INTERPHEX in 2015, where they ran a panel on CDMO executives’ perspectives. No decision has been announced regarding a possible follow-up section at INTERPHEX 2019, which takes place next April 2-4 at the Javits Center in New York City.
__________________________________________________________________________
References:
1 www.pharmpro.com
2 www.outsourcing-pharma.com; www.scribd.com
__________________________________________________________________________
This is an edited and updated version of an article that appeared in the INTERPHEX 2018 Show Daily: Tuesday, April 17.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
